HC Wainwright reissued their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS – Free Report) in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a $12.00 price target on the biotechnology company’s stock. Separately, Truist Financial cut their price target on shares of Coherus BioSciences from $8.00 to $7.00 […]
Coherus BioSciences (NASDAQ:CHRS) Receives Buy Rating from HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Coherus BioSciences, Inc (NASDAQ:CHRS) Receives Consensus Recommendation of Moderate Buy from Analysts dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price […]
E Fund Management Co. Ltd. purchased a new stake in Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 45,010 shares of the biotechnology company’s stock, valued at approximately $168,000. Several other institutional investors also recently bought and sold shares of […]